{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:44:29Z","timestamp":1793036669504,"version":"4.5.0"},"reference-count":25,"publisher":"Informa UK Limited","issue":"34","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,10,29]]},"DOI":"10.1080\/14796694.2024.2379233","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:51:38Z","timestamp":1723193498000},"page":"2637-2645","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Real-world first-line treatment patterns and outcomes in recurrent\/advanced endometrial cancer patients in Europe"],"prefix":"10.1080","volume":"20","author":[{"given":"Jingchuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Eisai Inc.,\u00a0RWE &amp; HEOR, Nutley, NJ\u00a007110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha S","family":"Kelkar","sequence":"additional","affiliation":[{"name":"OPEN Health,\u00a0Evidence &amp; Access, Bethesda, MD\u00a020814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimalanand S","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.,\u00a0Merck Research Laboratories, Rahway, NJ\u00a007065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoscar M","family":"Ogando","sequence":"additional","affiliation":[{"name":"OPEN Health,\u00a0Evidence &amp; Access, Bethesda, MD\u00a020814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-0466","authenticated-orcid":false,"given":"Rishi P","family":"Verma","sequence":"additional","affiliation":[{"name":"OPEN Health,\u00a0Evidence &amp; Access, Bethesda, MD\u00a020814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Grall","sequence":"additional","affiliation":[{"name":"M3 (EU) Ltd.,\u00a0medeConnect,\u00a0Abingdon, OX14 4RY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Marth","sequence":"additional","affiliation":[{"name":"Department of Obstetrics &amp; Gynecology, Medical University Innsbruck, Innsbruck, A-6020, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"e_1_3_8_3_1","unstructured":"The Global Cancer Observatory. Europe. Published March 2021. Accessed April 26 2023. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/908-europe-fact-sheets.pdf"},{"key":"e_1_3_8_4_1","article-title":"Corpus uteri - international agency for research on cancer","author":"The Global Cancer Observatory","unstructured":"The Global Cancer Observatory. Corpus uteri - international agency for research on cancer. Corpus Uteri. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/24-Corpus-uteri-fact-sheet.pdf. Published December 2020. Accessed February 28, 2023.","journal-title":"Corpus Uteri."},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0020-7292(03)90116-0"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.09.033"},{"issue":"3","key":"e_1_3_8_7_1","first-page":"179","article-title":"Factors predicting recurrent endometrial cancer","volume":"5","author":"Huijgens AN","year":"2013","unstructured":"Huijgens AN, Mertens HJ. Factors predicting recurrent endometrial cancer. Facts Views Vis Obgyn. 2013;5(3):179\u2013186.","journal-title":"Facts Views Vis Obgyn."},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21561"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.009"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv484"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_3_8_12_1","volume-title":"Survival Rates for Endometrial Cancer","author":"American Cancer Society","unstructured":"American Cancer Society. Survival Rates for Endometrial Cancer. Published March 1, 2023. Accessed May 9, 2023. https:\/\/www.cancer.org\/cancer\/types\/endometrial-cancer\/detection -diagnosis-staging\/survival-rates.html"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-017-0056-7"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211001199"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.10.041"},{"key":"e_1_3_8_16_1","volume-title":"European Commission approves GSK's JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer","author":"GlaxoSmithKline","year":"2021","unstructured":"GlaxoSmithKline. European Commission approves GSK's JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer. 2021."},{"key":"e_1_3_8_17_1","unstructured":"Merck & Co. Inc. . MSD European Commission Approves Merck's KEYTRUDA\u00ae (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer. 2022. https:\/\/www.merck.com\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-for-patients-with-microsatellite-instability-high-msi-h-or-deficient-mismatch-repair-dmmr-tumors-in-five-different-types\/"},{"key":"e_1_3_8_18_1","unstructured":"Merck & Co. Inc. . MSD European Commission Approves KEYTRUDA\u00ae (pembrolizumab) Plus LENVIMA (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma. 2021. https:\/\/www.merck.com\/news\/european-commission-approves-keytruda-pembrolizumab-plus-lenvima-lenvatinib-for-patients-with-certain-types-of-endometrial-carcinoma\/"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-ESGO.1115"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-079447"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-024-07504-3"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01076"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.12.008"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-ESGO.227"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-ESGO.383"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2379233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T12:20:53Z","timestamp":1730290853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2379233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":25,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2024,10,29]]}},"alternative-id":["10.1080\/14796694.2024.2379233"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2379233","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}